A comparative assessment of three serological methods for leprosy diagnosis (the fluorescent leprosy antibody absorption [FLA-ABS] test, the Mycobacterium leprae soluble-extract enzyme-linked immunosorbent assay [ELISA], and the M. leprae particle agglutination [MLPA] Leprosy is still a major health problem in many tropical and subtropical areas, where it afflicts approximately 12 million people, even though the total number of officially reported cases for 1990 was 3.7 million (31). Currently, leprosy is diagnosed and classified according to clinical, histopathological, and bacteriological criteria (9). Nevertheless, in many developing countries where leprosy is endemic, resources for these purposes are often very limited. Therefore, it is necessary to have simple, cost-effective, and rapid methodologies which could be complementary to or even substitute for conventional diagnostic procedures. Serodiagnosis is the most affordable alternative, and consequently several different tests for leprosy with a wide array of effectiveness have been proposed and evaluated (17, 24, 31) .
Leprosy is still a major health problem in many tropical and subtropical areas, where it afflicts approximately 12 million people, even though the total number of officially reported cases for 1990 was 3.7 million (31) . Currently, leprosy is diagnosed and classified according to clinical, histopathological, and bacteriological criteria (9) . Nevertheless, in many developing countries where leprosy is endemic, resources for these purposes are often very limited. Therefore, it is necessary to have simple, cost-effective, and rapid methodologies which could be complementary to or even substitute for conventional diagnostic procedures. Serodiagnosis is the most affordable alternative, and consequently several different tests for leprosy with a wide array of effectiveness have been proposed and evaluated (17, 24, 31) .
The aim of the present work was to assess the performance and effectiveness of three leprosy tests, two using a heterogenous mixture of antigens of Mycobacterium leprae, and the third using a specific antigenic derivative of the same agent. The first was the fluorescent leprosy antibody absorption (FLA-ABS) test, developed by Abe et al. (1) , which is an indirect immunofluorescence test with whole M. leprae as the antigen and suspicious sera previously absorbed with intact M. bovis BCG and M. vaccae and a cardiolipinlecithin solution. The second was an indirect enzyme-linked immunosorbent assay (ELISA) using plates coated with soluble antigen from sonicated M. leprae (28) . Finally, we included the M. leprae particle agglutination (MLPA) test (22) , a recently developed test involving passive agglutina-* Corresponding author. tion of sensitized gelatin particles with chemically synthesized M. leprae natural trisaccharide-phenyl propionatebovine serum albumin (NT-P-BSA).
Studied sera included samples obtained from 45 patients treated for lepromatous leprosy diagnosed and classified according to the standard clinical, histopathological, and bacteriological methods at the Centro Dermatologico Dr. Ladislao de la Pascua, Mexico City, Mexico. Also, 21 serum samples from newly discovered and untreated cases of pulmonary tuberculosis, all of which were identified after clinical manifestations and through culture-positive results at the Clinica de Enfermedades del Aparato Respiratorio, Secretaria de Salud, Mexico City, Mexico, were used. As healthy controls, two groups were selected. The first consisted of 99 serum samples from the area of Mexico with the highest rate of leprosy (the state of Sinaloa), where the leprosy rate is 1.28 cases per 1,000 inhabitants, and the second consisted of 99 serum specimens from Mexico City, where the prevalence of the disease is low (0.14 cases per 1,000 inhabitants). No known histories of direct contact with patients with leprosy or apparent manifestations of leprosy were reported either for tuberculosis cases or for healthy controls. All sera were kept frozen at -70°C until use.
For the FLA-ABS test, M. leprae grown in armadillos and supplied by E. E. Storrs, Medical Research Institute, Florida Institute of Technology, Melbourne, Fla., was purified from the liver by the method of Prabakaran et al. (27) . The acid-fast bacilli were counted by the method standardized by Shepard and McRae (30) [wt/ vol] ). After incubation at 37°C for 30 min, this mixture was centrifuged at 1,500 x g for 30 min at 4°C. The supernatant was filtered through a membrane filter with a 0.22-,um pore size to remove suspended particles. This solution was used as a secondary antibody in the test. Buffered glycerol was prepared with 1 volume of freshly prepared carbonate buffer, pH 9.5, and 9 volumes of glycerol (reagent grade nonfluorescent; E. Merck AG, Darmstadt, Germany). To prepare smears of M. leprae, 5 pl of the bacterial suspension containing 1.5 x 108 bacilli per ml was spread in a circle (1-cm diameter) marked on a glass slide used for immunofluorescence tests (M6177; American Scientific Products, McGaw Park, Ill.). The smear was air dried with a hair dryer. To eliminate remaining lipids, the smears were immersed in carbon tetrachloride at room temperature for 10 min. Contaminating armadillo tissue was digested with 0.1% trypsin solution at 37°C. Before use, the slides were washed three times with PBS (pH 7.2) for 5 min each time. For absorption, 0.2 ml of the test serum, 0.2 ml of the BCG suspension, 0.2 ml of the M. vaccae suspension, and 1.4 ml of diluent A were mixed. This mixture was incubated at 37°C for 30 min and centrifuged at 1,500 x g for 30 min. The supernatant was filtered through a 0.22-,um-pore-size membrane filter. For the test, smears of M. leprae were covered with the absorbed serum, incubated at 37°C for 1 h in a moist chamber, and washed three times with PBS, pH 7.2. The positive sera were titrated in fourfold dilutions up to 1:10,240 with diluent B. Smears were covered with anti-human globulin fluorescent-antibody solution and incubated at 4°C overnight in a moist chamber. They were washed as described above, and the smears were allowed to dry. We used a pool of five high-titer positive serum samples from patients with lepromatous leprosy as a positive control, and we used PBS, pH 7.2, and a pool of five serum samples from healthy individuals who lived in areas where leprosy is not endemic and who did not have a history of contact with leprosy patients as negative controls. All problem and control smears were mounted with carbonate-buffered glycerol, pH 9.5, and a coverslip. The quantitative gelatin particle agglutination test (MLPA) with particles sensitized with the semisynthetic trisaccharide of phenolic glycolipid I (PGL-I) (NT-P-BSA) was performed with a Serodia*-Leprae diagnostic kit (Fujirebio Inc., Tokyo, Japan), which was kindly donated by the manufacturer. Twofold serum dilutions from 1:4 to 1:4,096 were made in the wells of the supplied U-bottom microdilution plate. Twenty-five microliters of sensitized particles was added to each serum dilution, and after 2 h of incubation at room temperature, agglutination patterns were determined and interpreted according to the manufacturer's instructions. Positive results were recorded when agglutination was observed in the 1:32 final dilution and higher dilutions.
Specificity, sensitivity, and positive and negative predictive values were calculated for each test, by the method of Galen and Gambino (19) . The percent agreement between two tests was determined by the following formula: 100 x number of results in agreement/total number of samples tested. Comparison between each pair of procedures was tested by Cohen's kappa test (16) , and a 95% confidence interval was calculated. The K value was corrected for chance and ranged from -1 to 1, where a K of 1 indicates perfect agreement, a K of -1 indicates perfect disagreement, and a K of 0 indicates agreement expected by chance alone. Results showing the concordance between each pair of tests are given in Fig. 1 . No two tests agreed absolutely, and the differences observed could be attributed to reactivity with separate antigens or epitopes in each test, but further studies will be necessary to clarify this.
A low degree of specificity due to cross-reactive antibodies elicited by casual or deliberate contact with mycobacteria other than M. leprae is one of the most serious limitations in leprosy serodiagnosis. Hence, in order to seek the proportion of false-positive results due to these factors, the healthy controls used here were selected from two epidemiologically distinct areas, one of high endemicity and the other of low endemicity. For both groups, contact with environmental mycobacteria and the effect of BCG vaccination, which is still compulsory in Mexico, are the factors to be explored, (13) . It is highly probable that genetic traits, along with other factors yet to be defined, are responsible for such discrepancies. In this study, it was not possible to establish the origin of antibodies which gave positive reactions in healthy individuals, but the ages of positive controls displayed a random distribution, a fact which could rule out a major participation of antibodies generated after BCG vaccination and supports their probable presence due to frequent contact with environmental nonpathogenic mycobacteria. The case of M. tuberculosis is special because it is still a major pathogen in developing countries and very often its geographical distribution overlaps with that of M. leprae. Here, a small but highly representative sample of patients with confirmed, active, untreated pulmonary tuberculosis was selected and studied. The best results were obtained with the FLA-ABS test with no false-positive reactions, supporting similar data reported by us (4) as well as other authors (1, 23) . Undoubtedly, extensive absorption with whole-cell M. vaccae and M. bovis BCG is able to confer high specificity to the test. In contrast, the M. leprae extract ELISA resulted in the lowest mycobacterial specificity, a likely result of antigen sharing between M. leprae and other mycobacteria (34) . With the MLPA test, despite the recognized exclusiveness of PGL-I for M. leprae (33) , two of the tuberculosis patient samples were positive without a satisfactory explanation. Such a finding is not unusual, and in some but not all of the reported studies in which native PGL-I or its synthetic oligosaccharides were used, a few positive reactions in tuberculosis patients sera have occurred (12, 18, 26, 32 and indicates only that special care be taken in the interpretation of individual positive results.
The low sensitivity of the M. leprae extract ELISA (47%) resulting from the high number of false-positive reactions precludes its use in serodiagnosis of leprosy. Interestingly, a similar sensitivity for patients with lepromatous leprosy with a BCG extract ELISA has been reported (15) , suggesting that the reactivity of most antibodies in these patients is against antigens shared by both species.
The FLA-ABS test showed an outstanding sensitivity of 95% which, along with the aforementioned high specificity, makes it an excellent candidate to be used for a wide variety of leprosy studies, except for the assessment of treatment efficacy (2, 3, 7, 14, 20, 29) . Nevertheless, in developing countries it is difficult to set up this test because it is expensive and requires well-trained personnel for its correct interpretation. These features, along with the high proportion of household contacts who have antibodies detectable with the assay (1, 2, 4, 6, 21, 23 ), limits its performance to well-developed laboratories to be carried out as a confirmatory test for individuals with a definite clinical status and epidemiological background.
A remarkable decrease of anti-PGL-I antibodies after treatment has been observed with several methods (5, 8, 11, 12, 25) , including the MLPA test (10, 13, 22 
